


Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (Previously Presented): A δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide compound of formula (I)



wherein

- R^1 is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;
- R^2 is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl, optionally hydrogenated heteroaryl-lower alkyl, amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, lower alkenyloxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkenyl, lower alkenyloxy-lower alkoxy, lower alkoxy-lower alkenyloxy, lower alkenyloxy-lower alkyl, lower alkanoyl lower alkoxy, optionally *S*-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkyl, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkyl, cyano-lower alkoxy, cyano-lower alkyl, free or

esterified or amidated carboxy-lower alkoxy or free or esterified or amidated carboxy-lower alkyl;

R³ and R⁴ are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthio-lower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or *N,N*-disubstituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroarylthio-lower alkoxy; amino-lower alkoxy that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or substituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene, cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or

R⁴ together with R₃ is lower alkeneoxy, lower alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;

X is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen, optionally oxidized sulfur;

R⁵ is lower alkyl or cycloalkyl;

R⁶ is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;

R⁷ is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated or *N*-lower alkanoylated amino;

R⁸ is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;

R⁹ is optionally substituted cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 2 (Previously Presented): The compound according to claim 1 wherein

R^9 is optionally substituted cycloalkyl (alkyl, OH, alkoxy, alkoxy-alkyl, halogens);

or a pharmaceutically acceptable salt thereof.

Claim 3 (Previously Presented): The compound according to claim 2 wherein

R^1 and R^4 are hydrogen;

R^2 is lower alkoxy-lower alkoxy;

R^3 is halogen or mono, di or tri-halo-substituted alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 4 (Previously Presented): The compound according to claim 3 wherein the halogen/halo is fluorine or chlorine;

or a pharmaceutically acceptable salt thereof.

Claim 5 (Previously Presented): The compound according to claim 4 wherein

R^3 is fluorine or trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

Claim 6 (Previously Presented): The compound according to claim 5 wherein R^2 is in the meta position and R^3 is in the para position;

or a pharmaceutically acceptable salt thereof.

Claim 7 (Previously Presented): The compound according to claim 5 wherein R^3 is in the ortho position;

or a pharmaceutically acceptable salt thereof.

Claim 8 (Previously Presented): The compound according to claim 5 wherein R^3 is in the meta position;


or a pharmaceutically acceptable salt thereof.

Claim 9 (Previously Presented): The compound according to claim 2 wherein R² is in the meta position and is lower alkoxy-lower alkoxy optionally substituted by halogen(s);

or a pharmaceutically acceptable salt thereof.

Claims 10-18 (Cancelled)

Claim 19 (Previously Presented): The δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide compound according to claim 1 having formula (Ia)



wherein

R¹ is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;

R² is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkoxy, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, cycloalkoxy, lower alkenyloxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkenyl, lower alkenyloxy-lower alkoxy, lower alkoxy-lower alkenyloxy, lower alkenyloxy-lower alkyl, lower alkanoyl-lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkyl, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated hetero-

aryl-lower alkyl, cyano-lower alkoxy, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkoxy or free or esterified or amidated carboxy-lower alkyl;

R³ and R⁴ are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthio-lower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or *N,N*-disubstituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene; cyano-lower alkyl, free or esterified or amidated carboxy-lower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroarylthio-lower alkoxy; amino-lower alkoxy that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or substituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxalower alkylene or by optionally S-oxidised thia-lower alkylene; cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or

R⁴ together with R₃ is lower alkeneoxy, alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;

X is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen or optionally oxidized sulfur;

R⁵ is lower alkyl or cycloalkyl;

R⁶ is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;

R⁷ is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated or *N*-lower alkanoylated amino;

R⁸ is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;

R⁹ is optionally substituted cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 20 (Previously Presented): The compound according to claim 19 wherein

R⁹ is cycloalkyl substituted with alkyl, hydroxy, alkoxy, alkoxy-alkoxy or halogens;

or a pharmaceutically acceptable salt thereof.

Claim 21 (Previously Presented): The compound according to claim 19 wherein

R⁹ is cycloalkyl substituted by 1 to 3 substituents selected from the group consisting of alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxy-alkoxy, alkylthio, arylthio, aryl-alkoxy, carbamoyl, sulfamoyl, sulfonyl, optionally substituted amino, cyano, carboxy, alkoxycarbonyl, aryl, aryloxy, heterocyclyl or alkyl optionally substituted by amino, halo, hydroxy, alkoxy, carboxy, alkoxycarbonyl, carbamoyl or heterocyclyl;

or a pharmaceutically acceptable salt thereof.

Claim 22 (Previously Presented): The compound according to claim 21 wherein

R¹ is hydrogen;

R² is C₁-C₄ alkoxy – C₁-C₄ alkoxy or C₁-C₄ alkoxy – C₁-C₄ alkyl;

R³ is C₁-C₄ alkyl or C₁-C₄ alkoxy;

R⁴ is hydrogen;

X is methylene;

R⁵ is lower alkyl;

R⁶ is hydrogen;

R⁷ is unsubstituted amino;

R⁸ is branched C₃-C₄ alkyl;

R⁹ is optionally substituted cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 23 (Previously Presented): The compound according to claim 22 wherein

R² is 3-methoxypropyloxy;

R³ is methoxy;

R⁵ is isopropyl;

R⁸ is isopropyl;

or a pharmaceutically acceptable salt thereof.

Claim 24-29 (cancelled).

Claim 30 (Previously Presented): A pharmaceutical composition, comprising:

the compound according to claim 1 and

one or more pharmaceutically acceptable excipient(s).

Claim 31 - 38 (cancelled).

Claim 39 (Previously Presented) A compound named (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide, or a pharmaceutically acceptable salt thereof.

Claim 40 (Previously Presented) A compound named 1-[(2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoylamino]-cyclohexanecarboxylic acid methyl ester, or a pharmaceutically acceptable salt thereof.

Claim 41 (Previously Presented) A compound named (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid ((1S,2S)-2-hydroxy-cyclopentyl)-amide, or a pharmaceutically acceptable salt thereof.

Claim 42 (Previously Presented) A compound named (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid ((R)-2,2-dimethyl-cyclopentyl)-amide, or a pharmaceutically acceptable salt thereof.

Claim 43 (Cancelled).